News & Updates
Filter by Specialty:
Adjunctive semaglutide yields additional weight loss in teens with obesity
Once-weekly treatment with semaglutide, when administered with lifestyle intervention, leads to greater reduction in body mass index among adolescents with obesity as compared with lifestyle intervention alone, as shown in the STEP TEENS study.
Adjunctive semaglutide yields additional weight loss in teens with obesity
16 Nov 2022
Intensive BP-lowering a no-go after reperfusion in ischaemic stroke
An intensive blood pressure target (<120 mm Hg) should be avoided in patients who have undergone endovascular thrombectomy for acute ischaemic stroke (AIS) for large-vessel occlusion (LVO), results of the phase III ENCHANTED2/MT* trial showed.
Intensive BP-lowering a no-go after reperfusion in ischaemic stroke
14 Nov 2022
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
14 Nov 2022
Dolutegravir: A better choice for HIV viral suppression in pregnancy?
Among pregnant individuals on antiretroviral therapy (ART) for HIV-1 infection, those on dolutegravir had the greatest viral suppression rates at delivery, a recent US-based observational study showed. However, birth outcomes generally did not differ between dolutegravir recipients and those on various other ART regimens.